These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 527139)

  • 21. Mutagenicity of some derivatives of dipyrido[1,2-a:3',2'-d]imidazoles in Salmonella typhimurium with metabolic activation by rat liver and small intestine subcellular fractions.
    N'Goy K; Saint-Ruf G; de Meester C
    Mutat Res; 1985; 156(1-2):53-9. PubMed ID: 3889627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-covalent interaction with DNA of the mutagens 2-amino-dipyrido[1,2-a:3',2'-d]imidazole and methyl-substituted isomers.
    Imamura M; Takeda K; Shudo K; Okamoto T; Nagata C; Kodama M
    Biochem Biophys Res Commun; 1980 Sep; 96(2):611-7. PubMed ID: 7426002
    [No Abstract]   [Full Text] [Related]  

  • 23. Cytochrome P450 forms in the rodent lung involved in the metabolic activation of food-derived heterocyclic amines.
    Hellmold H; Overvik E; Strömstedt M; Gustafsson JA
    Carcinogenesis; 1993 Sep; 14(9):1751-7. PubMed ID: 8403195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic activation of 1-methyl-3-amino-5H-pyrido[4,3-b]indole and several structurally related mutagens.
    Pezzuto JM; Moore PD; Hecht SM
    Biochemistry; 1981 Jan; 20(2):298-305. PubMed ID: 7008841
    [No Abstract]   [Full Text] [Related]  

  • 25. Metabolic deactivation of mutagens in the Salmonella-microsome test.
    De Flora S
    Nature; 1978 Feb; 271(5644):455-6. PubMed ID: 342967
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparisons between in vivo and in vitro systems: the in vivo equivalent dose concept.
    Paolini M; Cantelli Forti G; Bauer C
    Mutagenesis; 1988 Nov; 3(6):527-31. PubMed ID: 3070294
    [No Abstract]   [Full Text] [Related]  

  • 27. DNA modification by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats.
    Takayama K; Yamashita K; Wakabayashi K; Sugimura T; Nagao M
    Jpn J Cancer Res; 1989 Dec; 80(12):1145-8. PubMed ID: 2516840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon.
    Turesky RJ; Lang NP; Butler MA; Teitel CH; Kadlubar FF
    Carcinogenesis; 1991 Oct; 12(10):1839-45. PubMed ID: 1934265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo N-acetylation of carcinogenic glutamic acid pyrolysis products in humans.
    Kanai Y; Manabe S; Wada O
    Carcinogenesis; 1988 Dec; 9(12):2179-84. PubMed ID: 3191562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of Binding of N-Hydroxy-TRP-P-2 to DNA by seryl-tRNA synthetase.
    Yamazoe Y; Tada M; Kamataki T; Kato R
    Biochem Biophys Res Commun; 1981 Sep; 102(1):432-9. PubMed ID: 6796088
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) by liver microsomes and isolated rabbit cytochrome P450 isozymes.
    Turteltaub KW; Knize MG; Buonarati MH; McManus ME; Veronese ME; Mazrimas JA; Felton JS
    Carcinogenesis; 1990 Jun; 11(6):941-6. PubMed ID: 2347068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zetidoline metabolism by rat liver microsomes. Formation of metabolites with potential neuroleptic activity.
    Assandri A; Galliani G; Zerilli L; Tuan G; Tarzia G; Barone D
    Biochem Pharmacol; 1986 May; 35(9):1459-67. PubMed ID: 2871840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) by human liver microsomes.
    Zhao K; Murray S; Davies DS; Boobis AR; Gooderham NJ
    Carcinogenesis; 1994 Jun; 15(6):1285-8. PubMed ID: 8020169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulfotransferase-mediated DNA binding of N-hydroxyarylamines(amide) in liver cytosols from human and experimental animals.
    Abu-Zeid M; Yamazoe Y; Kato R
    Carcinogenesis; 1992 Aug; 13(8):1307-14. PubMed ID: 1499081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-Glucuronidation of some 4-arylalkyl-1H-imidazoles by rat, dog, and human liver microsomes.
    Kaivosaari S; Salonen JS; Taskinen J
    Drug Metab Dispos; 2002 Mar; 30(3):295-300. PubMed ID: 11854148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of an ultimate mutagen of 10-azabenzo[a]pyrene: microsomal oxidation of 10-azabenzo[a]pyrene to 10-azabenzo[a]pyrene-4,5-oxide.
    Okuda H; Kitahara Y; Shudo K; Okamoto T
    Chem Pharm Bull (Tokyo); 1979 Oct; 27(10):2547-9. PubMed ID: 527140
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunological titration of 3-N-acetyl-hydroxyamino-4,6-dimethyldipyrido(1,2-a:3',2'-d) imidazole-rat liver DNA adducts.
    Hebert E; Saint-Ruf G; Leng M
    Carcinogenesis; 1985 Jun; 6(6):937-9. PubMed ID: 3874006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of nucleic acids with muta-carcinogenic heteroaromatic amines in vivo. Identification of modified bases in DNA extracted from rats injected with 3-amino-1-methyl-5H-pyrido[4,3-b]indole and 2-amino-6-methyldipyrido[1,2-a3:3',2'-d]imidazole.
    Hashimoto Y; Shudo K; Okamoto T
    Mutat Res; 1982 Aug; 105(1-2):9-13. PubMed ID: 7121483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative studies on the covalent binding of the carcinogen benzo(a)pyrene to DNA in various model systems.
    Jaggi W; Lutz WK; Schlatter C
    Experientia; 1979 May; 35(5):631-2. PubMed ID: 446661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transforming activity of human c-Ha-ras-1 proto-oncogene generated by the binding of 2-amino-6-methyl-dipyrido[1,2-a:3',2'-d]imidazole and 4-nitroquinoline N-oxide: direct evidence of cellular transformation by chemically modified DNA.
    Hashimoto Y; Kawachi E; Shudo K; Sekiya T; Sugimura T
    Jpn J Cancer Res; 1987 Mar; 78(3):211-5. PubMed ID: 3106276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.